Saurabh Chhabra

List of Publications by Year
in descending order

174 papers	4,405 citations	147801 31 h-index	144013 57 g-index
180 all docs	180 docs citations	180 times ranked	5257 citing authors

#	Article	IF	Citations
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	7.2	385
2	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 2020, 26, e177-e182.	2.0	378
3	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood, 2016, 127, 938-947.	1.4	246
4	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
5	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. JAMA Oncology, 2018, 4, 343.	7.1	130
6	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 2901-2912.	1.6	124
7	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. British Journal of Haematology, 2016, 174, 235-248.	2.5	115
8	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood, 2021, 138, 1278-1281.	1.4	101
9	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood, 2021, 138, 273-282.	1.4	88
10	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2019, 134, 860-860.	1.4	80
11	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1689-1694.	2.0	70
12	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
13	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
14	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer, 2018, 124, 2541-2551.	4.1	61
15	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	2.5	58
16	Diffuse large Bâ€cell lymphoma with primary treatment failure: Ultraâ€high risk features and benchmarking for experimental therapies. American Journal of Hematology, 2017, 92, 161-170.	4.1	56
17	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 2020, 135, 97-107.	1.4	56
18	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs, 2019, 37, 297-306.	2.6	51

#	Article	IF	Citations
19	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2020, 26, 1312-1317.	2.0	49
20	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	2.4	48
21	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	2.4	47
22	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer, 2020, 126, 5077-5087.	4.1	47
23	A phase 1 trial of SGNâ€CD70A in patients with CD70â€positive, metastatic renal cell carcinoma. Cancer, 2019, 125, 1124-1132.	4.1	41
24	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 362-368.	2.0	40
25	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€“Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	5.9	40
26	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Advances, 2020, 4, 467-476.	5.2	39
27	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, e161-e166.	2.0	38
28	Peripheral Blood Grafts for T Cellâ€“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1664-1670.	2.0	36
29	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
30	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
31	Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
32	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
33	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
34	Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR TÂcell, and BiTE recipients. Cancer Cell, 2022, 40, 340-342.	16.8	35
35	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 2020, 4, 983-992.	5.2	34
36	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals, 2017, 10, 40.	3.8	33

#	Article	IF	Citations
37	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30
38	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 651-651.	1.4	30
39	Multiple myeloma and COVID-19. Leukemia, 2020, 34, 1961-1963.	7.2	29
40	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances, 2022, 6, 2466-2470.	5.2	29
41	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer, 2018, 18, 593.	2.6	28
42	High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 77.	17.0	27
43	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
44	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 326-335.	0.4	27
45	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplantation and Cellular Therapy, 2022, 28, 409.e1-409.e10.	1.2	26
46	Second primary malignancy after multiple myelomaâ€population trends and causeâ€specific mortality. British Journal of Haematology, 2018, 182, 513-520.	2.5	25
47	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplantation, 2021, 56, 2763-2770.	2.4	25
48	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e46-e54.	2.0	24
49	<scp>Câ€MYC</scp>â€“positive relapsed and refractory, diffuse large <scp>B</scp>â€cell lymphoma: Impact of additional â€œhitsâ€•and outcomes with subsequent therapy. Cancer, 2017, 123, 4411-4418.	4.1	23
50	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 10-14.	0.9	23
51	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 827-833.	2.0	23
52	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2588-2594.	1.3	22
53	Survival outcomes of allogeneic hematopoietic cell transplants with EBVâ€positive or EBVâ€negative postâ€transplant lymphoproliferative disorder, A CIBMTR study. Transplant Infectious Disease, 2019, 21, e13145.	1.7	22
54	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21

#	Article	IF	Citations
55	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. Biology of Blood and Marrow Transplantation, 2019, 25, 921-931.	2.0	21
56	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. Journal of Hematology and Oncology, 2016, 9, 71.	17.0	20
57	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp>. American Journal of Hematology, 2021, 96, E5-E8.	4.1	20
58	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1379-1385.	2.0	19
59	Impact of type of reducedâ€intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. British Journal of Haematology, 2020, 190, 573-582.	2.5	19
60	Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 65-70.	0.9	19
61	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1456-1464.	2.0	18
62	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia, 2022, 36, 877-880.	7.2	18
63	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 911-917.	2.4	18
64	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemporary Clinical Trials Communications, 2017, 8, 33-38.	1.1	17
65	Allogeneic Transplantation for Relapsed WaldenstrÃ¶m Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 60-66.	2.0	17
66	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1670-1678.	2.0	17
67	Salvage second transplantation in relapsed multiple myeloma. Leukemia, 2021, 35, 1214-1217.	7.2	17
68	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 225-231.	2.4	17
69	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
70	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e145-e154.	2.0	16
71	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 56.	6.2	15
72	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15

#	Article	IF	Citations
73	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
74	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biology of Blood and Marrow Transplantation, 2019, 25, 1424-1431.	2.0	14
75	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
76	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. Leukemia and Lymphoma, 2020, 61, 869-874.	1.3	14
77	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
78	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological Oncology, 2020, 38, 353-362.	1.7	14
79	Breaking the Age Barrier: Physiciansâ€™ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and Cellular Therapy, 2021, 27, 617.e1-617.e7.	1.2	14
80	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
81	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
82	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biology of Blood and Marrow Transplantation, 2020, 26, 893-901.	2.0	13
83	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
84	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Network Open, 2019, 2, e196476.	5.9	12
85	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106.	2.0	12
86	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
87	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood, 2019, 134, 5329-5329.	1.4	12
88	Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL. Blood, 2015, 126, 1527-1527.	1.4	12
89	Monoclonal gammopathy of renal significance (MGRS): Realâ€world data on outcomes and prognostic factors. American Journal of Hematology, 2022, 97, 877-884.	4.1	12
90	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11

#	Article	IF	Citations
91	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 2011-2017.	2.0	11
92	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. Blood Advances, 2020, 4, 706-716.	5.2	11
93	Autonomic nervous system control of multiple myeloma. Blood Reviews, 2021, 46, 100741.	5.7	11
94	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
95	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11
96	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
97	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
98	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, e33-e38.	2.0	10
99	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, 1930-1936.	2.0	10
100	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biology of Blood and Marrow Transplantation, 2020, 26, 1288-1297.	2.0	10
101	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	1.4	10
102	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	1.4	10
103	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	2.5	9
104	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
105	Pharmacokinetics of High-Dose Propylene Glycolâ€“Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1610-1614.	2.0	8
106	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 2020, 191, 442-452.	2.5	8
107	Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 407-414.	0.4	8
108	Alphaâ€1â€antitrypsin for the treatment of steroidâ€refractory acute gastrointestinal graftâ€versusâ€host disease. American Journal of Hematology, 2017, 92, E610-E611.	4.1	7

#	Article	IF	Citations
109	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplantation, 2018, 53, 1210-1213.	2.4	7
110	Impact of autologous blood transfusion after bone marrow harvest on unrelated donorâ€™s health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
111	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Leukemia and Lymphoma, 2021, 62, 2094-2106.	1.3	7
112	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. Blood, 2021, 138, 2852-2852.	1.4	7
113	Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM). Blood, 2021, 138, 2838-2838.	1.4	7
114	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	1.3	6
115	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network metaâ€anâ€alysis of phase 3 randomized controlled trials. Cancer, 2020, 126, 2791-2801.	4.1	6
116	Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. Biology of Blood and Marrow Transplantation, 2020, 26, 1828-1832.	2.0	6
117	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
118	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. Blood, 2018, 132, 3233-3233.	1.4	6
119	Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma. Blood, 2020, 136, 29-30.	1.4	6
120	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood, 2015, 126, 377-377.	1.4	6
121	Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms. Advances in Radiation Oncology, 2022, 7, 100964.	1.2	6
122	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
123	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2229-2236.	2.0	4
124	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1876-1885.	2.0	4
125	Trends in the use of therapeutic plasma exchange in multiple myeloma. Journal of Clinical Apheresis, 2020, 35, 307-315.	1.3	4
126	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4

#	Article	IF	Citations
127	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e468-e473.	0.4	4
128	Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation. American Journal of the Medical Sciences, 2021, 362, 72-77.	1.1	4
129	Population-Level Trends in Early Mortality and Overall Survival of Patients with Multiple Myeloma. Are We Facing Stagnation?. Blood, 2019, 134, 4760-4760.	1.4	4
130	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	4.1	4
131	Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leukemia and Lymphoma, 2022, 63, 2507-2510.	1.3	4
132	An updated single center experience with plerixafor and granulocyte colonyâ€stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis, 2019, 34, 686-691.	1.3	3
133	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia and Lymphoma, 2019, 60, 940-946.	1.3	3
134	The Effect of Granulocyte Colony-Stimulating Factor Use on Hospital Length of Stay after Allogeneic Hematopoietic Cell Transplantation: A Retrospective Multicenter Cohort Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2359-2364.	2.0	3
135	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	1.3	3
136	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplantation and Cellular Therapy, 2021, 27, 142.e1-142.e11.	1.2	3
137	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	1.4	3
138	Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma. Blood, 2021, 138, 1626-1626.	1.4	3
139	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
140	Impact of autologous hematopoietic cell transplantation on disease burden quantified by nextâ€generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	4.1	3
141	Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 863-868.	0.4	3
142	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 210-215.	3.0	2
143	Laboratory Mice â€“ A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Frontiers in Immunology, 2021, 12, 667054.	4.8	2
144	Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM). Blood, 2019, 134, 783-783.	1.4	2

#	Article	IF	Citations
145	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. Blood, 2019, 134, 4516-4516.	1.4	2
146	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e495-e497.	0.4	2
147	IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. Annals of Clinical and Laboratory Science, 2017, 47, 611-619.	0.2	2
148	A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. Transplantation and Cellular Therapy, 2022, 28, 242-247.	1.2	2
149	Letter to the Editor Regarding â€œDiagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantationâ€. Biology of Blood and Marrow Transplantation, 2020, 26, e241-e242.	2.0	1
150	Pegfilgrastim 6 Mg Versus 12 Mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: Efficacy, Safety, and Cost Analysis. Blood, 2015, 126, 4306-4306.	1.4	1
151	The significance of beta-II microglobulin (Î²2M) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI).. Journal of Clinical Oncology, 2020, 38, 8544-8544.	1.6	1
152	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338.	2.5	1
153	Unrelated Donor Allogeneic Transplant. Organ and Tissue Transplantation, 2021, , 265-283.	0.0	0
154	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e775-e781.	0.4	0
155	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leukemia Research, 2021, 109, 106648.	0.8	0
156	Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkinâ€™s Lymphoma Have Been Exposed To It?. Blood, 2013, 122, 5552-5552.	1.4	0
157	Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience. Blood, 2014, 124, 5907-5907.	1.4	0
158	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. Blood, 2016, 128, 513-513.	1.4	0
159	Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma. Blood, 2016, 128, 4630-4630.	1.4	0
160	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. Blood, 2016, 128, 103-103.	1.4	0
161	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 8022-8022.	1.6	0
162	Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.. Journal of Clinical Oncology, 2017, 35, 7062-7062.	1.6	0

#	Article	IF	Citations
163	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	1.6	0
164	Allogeneic stem cell transplant (AHCT) in the eighth decade: Age is just a number.. Journal of Clinical Oncology, 2017, 35, 7045-7045.	1.6	0
165	Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8028-8028.	1.6	0
166	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018, 132, 3544-3544.	1.4	0
167	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018, 132, 617-617.	1.4	0
168	Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2019, 134, 3256-3256.	1.4	0
169	Fluconazole vs. voriconazole prophylaxis for prevention of invasive fungal infections post haploidentical stem cell transplant.. Journal of Clinical Oncology, 2020, 38, e19504-e19504.	1.6	0
170	Unrelated Donor Allogeneic Transplant. Organ and Tissue Transplantation, 2021, , 1-19.	0.0	0
171	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	1.4	0
172	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	1.4	0
173	Rap1A, Rap1B, and Î²-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.. Yale Journal of Biology and Medicine, 2022, 95, 45-56.	0.2	0
174	Kinetics of humoral immunodeficiency with bispecific antibody therapy in multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8049-8049.	1.6	0